Neuroinflammation in hypertension: the renin-angiotensin system versus pro-resolution pathways

Pharmacological Research

Volumn 144, Issue , 2019, Pages 279-291

  Mowry, Francesca Elisabeth ^a   Biancardi, Vinicia Campana ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

Angiotensin (1 7) (PubChem CID: 71434130); Angiotensin 1 7; Angiotensin II; Angiotensin II (PubChem CID: 172198); AVE0991 (PubChem CID: 78357809); BML 111 (PubChem CID: 10899465); Captopril (PubChem CID: 44093); central nervous system; Hydralazine (PubChem CID: 3637); hypertension; Losartan (PubChem CID: 3961); LXA4 ME (PubChem CID: 5280914); Minocycline (PubChem CID: 54675783); mitoTEMPO (PubChem CID: 135653355); RAS; resolution of inflammation

Indexed keywords

ANGIOTENSIN II; CANDESARTAN; CAPTOPRIL; HYDRALAZINE; LOSARTAN; N ETHYLCARBAMOYL 3 [4 (5 FORMYL 4 METHOXY 2 PHENYL 1 IMIDAZOLYLMETHYL)PHENYL] 5 ISOBUTYL 2 THIOPHENESULFONAMIDE; OMEGA 3 FATTY ACID; PERINDOPRIL; TOLL LIKE RECEPTOR 4;

BLOOD BRAIN BARRIER; GLIA CELL; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; ANIMAL; COMPLICATION; IMMUNOLOGY; INFLAMMATION; NEUROLOGIC DISEASE;

ANIMALS; FATTY ACIDS, OMEGA-3; HUMANS; HYPERTENSION; INFLAMMATION; NERVOUS SYSTEM DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 85064938384     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2019.04.029     Document Type: Review

References (283)

1. Mills, K.T., Bundy, J.D., Kelly, T.N., Reed, J.E., Kearney, P.M., Reynolds, K., Chen, J., He, J., Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation 134:6 (2016), 441–450.
2. Acelajado, M.C., Hughes, Z.H., Oparil, S., Calhoun, D.A., Treatment of Resistant and Refractory Hypertension. Circ Res. 124:7 (2019), 1061–1070.
3. Stocker, S.D., Kinsman, B.J., Sved, A.F., Recent Advances in Neurogenic Hypertension: Dietary Salt, Obesity, and Inflammation. Hypertension, 2017.
4. Balakumar, P., Jagadeesh, G., A century old renin-angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cell Signal. 26:10 (2014), 2147–2160.
5. de Morais, S.D.B., Shanks, J., Zucker, I.H., Integrative Physiological Aspects of Brain RAS in Hypertension. Curr Hypertens Rep., 20(2), 2018, 10.
6. Ganten, D., Hermann, K., Bayer, C., Unger, T., Lang, R.E., Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science 221:4613 (1983), 869–871.
7. Reaux, A., Fournie-Zaluski, M.C., David, C., Zini, S., Roques, B.P., Corvol, P., Llorens-Cortes, C., Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci U S A. 96:23 (1999), 13415–13420.
8. Basso, N., Ruiz, P., Mangiarua, E., Taquini, A.C., Renin-like activity in the rat brain during the development of DOC-salt hypertension. Hypertension 3:6 Pt 2 (1981), II-14–II-17.
9. Winklewski, P.J., Radkowski, M., Wszedybyl-Winklewska, M., Demkow, U., Brain inflammation and hypertension: the chicken or the egg?. J Neuroinflammation, 12, 2015, 85.
10. Schiavone, M.T., Santos, R.A., Brosnihan, K.B., Khosla, M.C., Ferrario, C.M., Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci U S A. 85:11 (1988), 4095–4098.
11. Santos, R.A., Simoes e Silva, A.C., Maric, C., Silva, D.M., Machado, R.P., de Buhr, I., Heringer-Walther, S., Pinheiro, S.V., Lopes, M.T., Bader, M., Mendes, E.P., Lemos, V.S., Campagnole-Santos, M.J., Schultheiss, H.P., Speth, R., Walther, T., Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A. 100:14 (2003), 8258–8263.
12. Santos, R.A., Brosnihan, K.B., Chappell, M.C., Pesquero, J., Chernicky, C.L., Greene, L.J., Ferrario, C.M., Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 11:2 Pt 2 (1988), I153–I157.
13. Campagnole-Santos, M.J., Diz, D.I., Santos, R.A., Khosla, M.C., Brosnihan, K.B., Ferrario, C.M., Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol. 257:1 Pt 2 (1989), H324–H329.
14. Bader, M., Alenina, N., Andrade-Navarro, M.A., Santos, R.A., MAS and its related G protein-coupled receptors. Mrgprs. Pharmacol Rev. 66:4 (2014), 1080–1105.
15. Santos, R.A.S., Sampaio, W.O., Alzamora, A.C., Motta-Santos, D., Alenina, N., Bader, M., Campagnole-Santos, M.J., The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol Rev. 98:1 (2018), 505–553.
16. Hammer, A., Stegbauer, J., Linker, R.A., Macrophages in neuroinflammation: role of the renin-angiotensin-system. Pflugers Arch. 469:3–4 (2017), 431–444.
17. Serhan, C.N., Chiang, N., Novel endogenous small molecules as the checkpoint controllers in inflammation and resolution: entree for resoleomics. Rheum Dis Clin North Am. 30:1 (2004), 69–95.
18. Mozaffarian, D., Wu, J.H., Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 58:20 (2011), 2047–2067.
19. Fullerton, J.N., Gilroy, D.W., Resolution of inflammation: a new therapeutic frontier. Nat Rev Drug Discov. 15:8 (2016), 551–567.
20. Serhan, C.N., Savill, J., Resolution of inflammation: the beginning programs the end. Nat Immunol. 6:12 (2005), 1191–1197.
21. Medzhitov, R., Origin and physiological roles of inflammation. Nature 454:7203 (2008), 428–435.
22. Cardinale, J.P., Sriramula, S., Mariappan, N., Agarwal, D., Francis, J., Angiotensin II-induced hypertension is modulated by nuclear factor-kappaBin the paraventricular nucleus. Hypertension 59:1 (2012), 113–121.
23. Kang, Y.M., Zhang, D.M., Yu, X.J., Yang, Q., Qi, J., Su, Q., Suo, Y.P., Yue, L.Y., Zhu, G.Q., Qin, D.N., Chronic infusion of enalaprilat into hypothalamic paraventricular nucleus attenuates angiotensin II-induced hypertension and cardiac hypertrophy by restoring neurotransmitters and cytokines. Toxicol Appl Pharmacol. 274:3 (2014), 436–444.
24. Shi, P., Diez-Freire, C., Jun, J.Y., Qi, Y., Katovich, M.J., Li, Q., Sriramula, S., Francis, J., Sumners, C., Raizada, M.K., Brain microglial cytokines in neurogenic hypertension. Hypertension 56:2 (2010), 297–303.
25. Kang, Y.M., Ma, Y., Zheng, J.P., Elks, C., Sriramula, S., Yang, Z.M., Francis, J., Brain nuclear factor-kappa B activation contributes to neurohumoral excitation in angiotensin II-induced hypertension. Cardiovasc Res. 82:3 (2009), 503–512.
26. Bai, J., Yu, X.J., Liu, K.L., Wang, F.F., Jing, G.X., Li, H.B., Zhang, Y., Huo, C.J., Li, X., Gao, H.L., Qi, J., Kang, Y.M., Central administration of tert-butylhydroquinone attenuates hypertension via regulating Nrf2 signaling in the hypothalamic paraventricular nucleus of hypertensive rats. Toxicol Appl Pharmacol. 333 (2017), 100–109.
27. Cheng, W.H., Lu, P.J., Ho, W.Y., Tung, C.S., Cheng, P.W., Hsiao, M., Tseng, C.J., Angiotensin II inhibits neuronal nitric oxide synthase activation through the ERK1/2-RSK signaling pathway to modulate central control of blood pressure. Circ Res. 106:4 (2010), 788–795.
28. Obermeier, B., Daneman, R., Ransohoff, R.M., Development, maintenance and disruption of the blood-brain barrier. Nat Med. 19:12 (2013), 1584–1596.
29. Erickson, M.A., Banks, W.A., Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions. Pharmacol Rev. 70:2 (2018), 278–314.
30. Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A.R., Zlokovic, B.V., Blood-Brain Barrier: From Physiology to Disease and Back. Physiol Rev. 99:1 (2019), 21–78.
31. Ferguson, A.V., Angiotensinergic regulation of autonomic and neuroendocrine outputs: critical roles for the subfornical organ and paraventricular nucleus. Neuroendocrinology 89:4 (2009), 370–376.
32. McKinley, M.J., Albiston, A.L., Allen, A.M., Mathai, M.L., May, C.N., McAllen, R.M., Oldfield, B.J., Mendelsohn, F.A., Chai, S.Y., The brain renin-angiotensin system: location and physiological roles. Int J Biochem Cell Biol. 35:6 (2003), 901–918.
33. Biancardi, V.C., Son, S.J., Ahmadi, S., Filosa, J.A., Stern, J.E., Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier. Hypertension 63:3 (2014), 572–579.
34. Biancardi, V.C., Stranahan, A.M., Krause, E.G., de Kloet, A.D., Stern, J.E., Cross talk between AT1 receptors and Toll-like receptor 4 in microglia contributes to angiotensin II-derived ROS production in the hypothalamic paraventricular nucleus. Am J Physiol Heart Circ Physiol. 310:3 (2016), H404–H415.
35. Setiadi, A., Korim, W.S., Elsaafien, K., Yao, S.T., The role of the blood-brain barrier in hypertension. Exp Physiol. 103:3 (2018), 337–342.
36. Yu, Y., Zhang, Z.H., Wei, S.G., Serrats, J., Weiss, R.M., Felder, R.B., Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction. Hypertension 55:3 (2010), 652–659.
37. Felder, R.B., Mineralocorticoid receptors, inflammation and sympathetic drive in a rat model of systolic heart failure. Exp Physiol. 95:1 (2010), 19–25.
38. Schiltz, J.C., Sawchenko, P.E., Signaling the brain in systemic inflammation: the role of perivascular cells. Front Biosci. 8 (2003), s1321–s1329.
39. Faraco, G., Sugiyama, Y., Lane, D., Garcia-Bonilla, L., Chang, H., Santisteban, M.M., Racchumi, G., Murphy, M., Van Rooijen, N., Anrather, J., Iadecola, C., Perivascular macrophages mediate the neurovascular and cognitive dysfunction associated with hypertension. J Clin Invest. 126:12 (2016), 4674–4689.
40. Williams, K., Alvarez, X., Lackner, A.A., Central nervous system perivascular cells are immunoregulatory cells that connect the CNS with the peripheral immune system. Glia 36:2 (2001), 156–164.
41. Qi, J., Zhang, D.M., Suo, Y.P., Song, X.A., Yu, X.J., Elks, C., Lin, Y.X., Xu, Y.Y., Zang, W.J., Zhu, Z., Kang, Y.M., Renin-angiotensin system modulates neurotransmitters in the paraventricular nucleus and contributes to angiotensin II-induced hypertensive response. Cardiovasc Toxicol. 13:1 (2013), 48–54.
42. Benicky, J., Sanchez-Lemus, E., Honda, M., Pang, T., Orecna, M., Wang, J., Leng, Y., Chuang, D.M., Saavedra, J.M., Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology 36:4 (2011), 857–870.
43. Benicky, J., Sanchez-Lemus, E., Pavel, J., Saavedra, J.M., Anti-inflammatory effects of angiotensin receptor blockers in the brain and the periphery. Cell Mol Neurobiol. 29:6-7 (2009), 781–792.
44. Shi, Z., Jiang, S.J., Wang, G.H., Xu, A.L., Guo, L., Pro-inflammatory cytokines in paraventricular nucleus mediate the cardiac sympathetic afferent reflex in hypertension. Auton Neurosci. 186 (2014), 54–61.
45. Zubcevic, J., Waki, H., Raizada, M.K., Paton, J.F., Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension 57:6 (2011), 1026–1033.
46. Schwartz, M., Kipnis, J., Rivest, S., Prat, A., How do immune cells support and shape the brain in health, disease, and aging?. J Neurosci. 33:45 (2013), 17587–17596.
47. Ransohoff, R.M., Brown, M.A., Innate immunity in the central nervous system. J Clin Invest. 122:4 (2012), 1164–1171.
48. Wolf, S.A., Boddeke, H.W., Kettenmann, H., Microglia in Physiology and Disease. Annu Rev Physiol. 79 (2017), 619–643.
49. Verkhratsky, A., Nedergaard, M., Physiology of Astroglia. Physiol Rev. 98:1 (2018), 239–389.
50. Sofroniew, M.V., Astrocyte barriers to neurotoxic inflammation. Nat Rev Neurosci. 16:5 (2015), 249–263.
51. Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 9:1 (2008), 46–56.
52. Doorduin, J., de Vries, E.F., Willemsen, A.T., de Groot, J.C., Dierckx, R.A., Klein, H.C., Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med. 50:11 (2009), 1801–1807.
53. Glass, C.K., Saijo, K., Winner, B., Marchetto, M.C., Gage, F.H., Mechanisms underlying inflammation in neurodegeneration. Cell 140:6 (2010), 918–934.
54. Gonzalez, H., Elgueta, D., Montoya, A., Pacheco, R., Neuroimmune regulation of microglial activity involved in neuroinflammation and neurodegenerative diseases. J Neuroimmunol. 274:1-2 (2014), 1–13.
55. Heneka, M.T., Carson, M.J., El Khoury, J., Landreth, G.E., Brosseron, F., Feinstein, D.L., Jacobs, A.H., Wyss-Coray, T., Vitorica, J., Ransohoff, R.M., Herrup, K., Frautschy, S.A., Finsen, B., Brown, G.C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G.C., Town, T., Morgan, D., Shinohara, M.L., Perry, V.H., Holmes, C., Bazan, N.G., Brooks, D.J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C.A., Breitner, J.C., Cole, G.M., Golenbock, D.T., Kummer, M.P., Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14:4 (2015), 388–405.
56. Bhat, S.A., Goel, R., Shukla, S., Shukla, R., Hanif, K., Angiotensin Receptor Blockade by Inhibiting Glial Activation Promotes Hippocampal Neurogenesis Via Activation of Wnt/beta-Catenin Signaling in Hypertension. Mol Neurobiol. 55:6 (2018), 5282–5298.
57. Carnevale, D., Mascio, G., Ajmone-Cat, M.A., D'Andrea, I., Cifelli, G., Madonna, M., Cocozza, G., Frati, A., Carullo, P., Carnevale, L., Alleva, E., Branchi, I., Lembo, G., Minghetti, L., Role of neuroinflammation in hypertension-induced brain amyloid pathology. Neurobiol Aging., 33(1), 2012 205 e219–e229.
58. Carreno-Muller, E., Herrera, A.J., de Pablos, R.M., Tomas-Camardiel, M., Venero, J.L., Cano, J., Machado, A., Thrombin induces in vivo degeneration of nigral dopaminergic neurones along with the activation of microglia. J Neurochem. 84:5 (2003), 1201–1214.
59. Torika, N., Asraf, K., Roasso, E., Danon, A., Fleisher-Berkovich, S., Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer's Disease. J Neuroimmune Pharmacol. 11:4 (2016), 774–785.
60. Shi, P., Grobe, J.L., Desland, F.A., Zhou, G., Shen, X.Z., Shan, Z., Liu, M., Raizada, M.K., Sumners, C., Direct pro-inflammatory effects of prorenin on microglia. PLoS One, 9(10), 2014, e92937.
61. Shen, X.Z., Li, Y., Li, L., Shah, K.H., Bernstein, K.E., Lyden, P., Shi, P., Microglia participate in neurogenic regulation of hypertension. Hypertension 66:2 (2015), 309–316.
62. Stern, J.E., Son, S., Biancardi, V.C., Zheng, H., Sharma, N., Patel, K.P., Astrocytes Contribute to Angiotensin II Stimulation of Hypothalamic Neuronal Activity and Sympathetic Outflow. Hypertension 68:6 (2016), 1483–1493.
63. Morales, I., Guzman-Martinez, L., Cerda-Troncoso, C., Farias, G.A., Maccioni, R.B., Neuroinflammation in the pathogenesis of Alzheimer's disease. A rational framework for the search of novel therapeutic approaches. Front Cell Neurosci., 8, 2014, 112.
64. Kawai, T., Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 11:5 (2010), 373–384.
65. Matzinger, P., The danger model: a renewed sense of self. Science 296:5566 (2002), 301–305.
66. Kawai, T., Akira, S., Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 34:5 (2011), 637–650.
67. Biancardi, V.C., Bomfim, G.F., Reis, W.L., Al-Gassimi, S., Nunes, K.P., The interplay between Angiotensin II, TLR4 and hypertension. Pharmacol Res. 120 (2017), 88–96.
68. Akira, S., Takeda, K., Toll-like receptor signalling. Nat Rev Immunol. 4:7 (2004), 499–511.
69. Nunes, K.P., de Oliveira, A.A., Mowry, F.E., Biancardi, V.C., Targeting TLR4 signaling pathways: can therapeutics pay the toll for hypertension?. Br J Pharmacol., 2018.
70. Tartey, S., Takeuchi, O., Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells. Int Rev Immunol. 36:2 (2017), 57–73.
71. Hanke, M.L., Kielian, T., Toll-like receptors in health and disease in the brain: mechanisms and therapeutic potential. Clin Sci (Lond). 121:9 (2011), 367–387.
72. Lehnardt, S., Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia 58:3 (2010), 253–263.
73. Dange, R.B., Agarwal, D., Masson, G.S., Vila, J., Wilson, B., Nair, A., Francis, J., Central blockade of TLR4 improves cardiac function and attenuates myocardial inflammation in angiotensin II-induced hypertension. Cardiovasc Res. 103:1 (2014), 17–27.
74. Dange, R.B., Agarwal, D., Teruyama, R., Francis, J., Toll-like receptor 4 inhibition within the paraventricular nucleus attenuates blood pressure and inflammatory response in a genetic model of hypertension. J Neuroinflammation., 12, 2015, 31.
75. Li, H.-B., Li, X., Huo, C.-J., Su, Q., Guo, J., Yuan, Z.-Y., Zhu, G.-Q., Shi, X.-L., Liu, J.-J., Kang, Y.-M., TLR4/MyD88/NF-κB signaling and PPAR-γ within the paraventricular nucleus are involved in the effects of telmisartan in hypertension. Toxicology and applied pharmacology 305 (2016), 93–102.
76. Ahmad, R., Al-Mass, A., Atizado, V., Al-Hubail, A., Al-Ghimlas, F., Al-Arouj, M., Bennakhi, A., Dermime, S., Behbehani, K., Elevated expression of the toll like receptors 2 and 4 in obese individuals: its significance for obesity-induced inflammation. J Inflamm (Lond)., 9(1), 2012, 48.
77. Singh, M.V., Chapleau, M.W., Harwani, S.C., Abboud, F.M., The immune system and hypertension. Immunol Res. 59:1–3 (2014), 243–253.
78. Bhatia, K., Elmarakby, A.A., El-Remessy, A.B., Sullivan, J.C., Oxidative stress contributes to sex differences in angiotensin II-mediated hypertension in spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol. 302:2 (2012), R274–R282.
79. Jia, Z., Aoyagi, T., Yang, T., mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP. Hypertension 55:2 (2010), 539–546.
80. Lob, H.E., Vinh, A., Li, L., Blinder, Y., Offermanns, S., Harrison, D.G., Role of vascular extracellular superoxide dismutase in hypertension. Hypertension. 58:2 (2011), 232–239.
81. Rey, F.E., Cifuentes, M.E., Kiarash, A., Quinn, M.T., Pagano, P.J., Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res. 89:5 (2001), 408–414.
82. Wilcox, C.S., Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther. 126:2 (2010), 119–145.
83. Torok, J., Participation of nitric oxide in different models of experimental hypertension. Physiol Res. 57:6 (2008), 813–825.
84. Case, A.J., Tian, J., Zimmerman, M.C., Increased mitochondrial superoxide in the brain, but not periphery, sensitizes mice to angiotensin II-mediated hypertension. Redox Biol. 11 (2017), 82–90.
85. Dikalova, A.E., Bikineyeva, A.T., Budzyn, K., Nazarewicz, R.R., McCann, L., Lewis, W., Harrison, D.G., Dikalov, S.I., Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res. 107:1 (2010), 106–116.
86. Dominiak, A., Wilkaniec, A., Jesko, H., Czapski, G.A., Lenkiewicz, A.M., Kurek, E., Wroczynski, P., Adamczyk, A., Selol, an organic selenium donor, prevents lipopolysaccharide-induced oxidative stress and inflammatory reaction in the rat brain. Neurochem Int. 108 (2017), 66–77.
87. Kishi, T., Hirooka, Y., Kimura, Y., Ito, K., Shimokawa, H., Takeshita, A., Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 109:19 (2004), 2357–2362.
88. Kishi, T., Hirooka, Y., Konno, S., Sunagawa, K., Sympathoinhibition induced by centrally administered atorvastatin is associated with alteration of NAD(P)H and Mn superoxide dismutase activity in rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol. 55:2 (2010), 184–190.
89. Motaghinejad, M., Motevalian, M., Shabab, B., Effects of chronic treatment with methylphenidate on oxidative stress and inflammation in hippocampus of adult rats. Neurosci Lett. 619 (2016), 106–113.
90. Savalia, K., Manickam, D.S., Rosenbaugh, E.G., Tian, J., Ahmad, I.M., Kabanov, A.V., Zimmerman, M.C., Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration. Free Radic Biol Med. 73 (2014), 299–307.
91. Su, Q., Liu, J.J., Cui, W., Shi, X.L., Guo, J., Li, H.B., Huo, C.J., Miao, Y.W., Zhang, M., Yang, Q., Kang, Y.M., Alpha lipoic acid supplementation attenuates reactive oxygen species in hypothalamic paraventricular nucleus and sympathoexcitation in high salt-induced hypertension. Toxicol Lett. 241 (2016), 152–158.
92. Zhang, D., Liu, J., Tu, H., Muelleman, R.L., Cornish, K.G., Li, Y.L., In vivo transfection of manganese superoxide dismutase gene or nuclear factor kappaB shRNA in nodose ganglia improves aortic baroreceptor function in heart failure rats. Hypertension 63:1 (2014), 88–95.
93. Zimmerman, M.C., Lazartigues, E., Sharma, R.V., Davisson, R.L., Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res. 95:2 (2004), 210–216.
94. Chen, Q., Pan, H.L., Signaling mechanisms of angiotensin II-induced attenuation of GABAergic input to hypothalamic presympathetic neurons. J Neurophysiol. 97:5 (2007), 3279–3287.
95. Yu, Y., Zhong, M.K., Li, J., Sun, X.L., Xie, G.Q., Wang, W., Zhu, G.Q., Endogenous hydrogen peroxide in paraventricular nucleus mediating cardiac sympathetic afferent reflex and regulating sympathetic activity. Pflugers Arch. 454:4 (2007), 551–557.
96. Nishihara, M., Hirooka, Y., Kishi, T., Sunagawa, K., Different role of oxidative stress in paraventricular nucleus and rostral ventrolateral medulla in cardiovascular regulation in awake spontaneously hypertensive rats. J Hypertens. 30:9 (2012), 1758–1765.
97. Nishihara, M., Hirooka, Y., Matsukawa, R., Kishi, T., Sunagawa, K., Oxidative stress in the rostral ventrolateral medulla modulates excitatory and inhibitory inputs in spontaneously hypertensive rats. J Hypertens. 30:1 (2012), 97–106.
98. Grote, K., Ortmann, M., Salguero, G., Doerries, C., Landmesser, U., Luchtefeld, M., Brandes, R.P., Gwinner, W., Tschernig, T., Brabant, E.G., Klos, A., Schaefer, A., Drexler, H., Schieffer, B., Critical role for p47phox in renin-angiotensin system activation and blood pressure regulation. Cardiovasc Res. 71:3 (2006), 596–605.
99. Haque, M.Z., Majid, D.S., High salt intake delayed angiotensin II-induced hypertension in mice with a genetic variant of NADPH oxidase. Am J Hypertens. 24:1 (2011), 114–118.
100. Wu, K.L.H., Wu, C.W., Chao, Y.M., Hung, C.Y., Chan, J.Y.H., Impaired Nrf2 regulation of mitochondrial biogenesis in rostral ventrolateral medulla on hypertension induced by systemic inflammation. Free Radic Biol Med. 97 (2016), 58–74.
101. Chan, S.H., Wu, C.A., Wu, K.L., Ho, Y.H., Chang, A.Y., Chan, J.Y., Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension. Circ Res. 105:9 (2009), 886–896.
102. Chan, S.H., Wu, C.W., Chang, A.Y., Hsu, K.S., Chan, J.Y., Transcriptional upregulation of brain-derived neurotrophic factor in rostral ventrolateral medulla by angiotensin II: significance in superoxide homeostasis and neural regulation of arterial pressure. Circ Res. 107:9 (2010), 1127–1139.
103. Chan, S.H., Wu, K.L., Chang, A.Y., Tai, M.H., Chan, J.Y., Oxidative impairment of mitochondrial electron transport chain complexes in rostral ventrolateral medulla contributes to neurogenic hypertension. Hypertension 53:2 (2009), 217–227.
104. Li, S., Case, A.J., Yang, R.F., Schultz, H.D., Zimmerman, M.C., Over-expressed copper/zinc superoxide dismutase localizes to mitochondria in neurons inhibiting the angiotensin II-mediated increase in mitochondrial superoxide. Redox Biol. 2 (2013), 8–14.
105. Nozoe, M., Hirooka, Y., Koga, Y., Araki, S., Konno, S., Kishi, T., Ide, T., Sunagawa, K., Mitochondria-derived reactive oxygen species mediate sympathoexcitation induced by angiotensin II in the rostral ventrolateral medulla. J Hypertens. 26:11 (2008), 2176–2184.
106. Wang, H.W., Huang, B.S., White, R.A., Chen, A., Ahmad, M., Leenen, F.H., Mineralocorticoid and angiotensin II type 1 receptors in the subfornical organ mediate angiotensin II - induced hypothalamic reactive oxygen species and hypertension. Neuroscience 329 (2016), 112–121.
107. Young, C.N., Li, A., Dong, F.N., Horwath, J.A., Clark, C.G., Davisson, R.L., Endoplasmic reticulum and oxidant stress mediate nuclear factor-kappaB activation in the subfornical organ during angiotensin II hypertension. Am J Physiol Cell Physiol. 308:10 (2015), C803–812.
108. Lob, H.E., Marvar, P.J., Guzik, T.J., Sharma, S., McCann, L.A., Weyand, C., Gordon, F.J., Harrison, D.G., Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension 55:2 (2010), 277–283 276p following 283.
109. Chan, S.H., Chan, J.Y., Angiotensin-generated reactive oxygen species in brain and pathogenesis of cardiovascular diseases. Antioxid Redox Signal. 19:10 (2013), 1074–1084.
110. Chan, S.H., Wu, K.L., Kung, P.S., Chan, J.Y., Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertension 55:6 (2010), 1444–1453.
111. Lu, M., Sun, X.L., Qiao, C., Liu, Y., Ding, J.H., Hu, G., Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like receptor protein 3 inflammasome activation. Neurobiol Aging. 35:2 (2014), 421–430.
112. Mehta, J.L., Lopez, L.M., Chen, L., Cox, O.E., Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and effects of celiprolol. Am J Cardiol. 74:9 (1994), 901–905.
113. Schmid-Schonbein, G.W., Seiffge, D., DeLano, F.A., Shen, K., Zweifach, B.W., Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension 17:3 (1991), 323–330.
114. Shen, K., Sung, K.L., Whittemore, D.E., DeLano, F.A., Zweifach, B.W., Schmid-Schonbein, G.W., Properties of circulating leukocytes in spontaneously hypertensive rats. Biochem Cell Biol. 73:7-8 (1995), 491–500.
115. Ohmori, M., Kitoh, Y., Harada, K., Sugimoto, K., Fujimura, A., Polymorphonuclear leukocytes (PMNs) functions in SHR, L-NAME- and DOCA/salt-induced hypertensive rats. J Hypertens. 18:6 (2000), 703–707.
116. Dantzer, R., Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. Physiol Rev. 98:1 (2018), 477–504.
117. Elenkov, I.J., Wilder, R.L., Chrousos, G.P., Vizi, E.S., The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev. 52:4 (2000), 595–638.
118. Zlokovic, B.V., The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57:2 (2008), 178–201.
119. Marvar, P.J., Thabet, S.R., Guzik, T.J., Lob, H.E., McCann, L.A., Weyand, C., Gordon, F.J., Harrison, D.G., Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res. 107:2 (2010), 263–270.
120. Pollow, D.P., Uhrlaub, J., Romero-Aleshire, M., Sandberg, K., Nikolich-Zugich, J., Brooks, H.L., Hay, M., Sex differences in T-lymphocyte tissue infiltration and development of angiotensin II hypertension. Hypertension 64:2 (2014), 384–390.
121. Santisteban, M.M., Ahmari, N., Carvajal, J.M., Zingler, M.B., Qi, Y., Kim, S., Joseph, J., Garcia-Pereira, F., Johnson, R.D., Shenoy, V., Raizada, M.K., Zubcevic, J., Involvement of bone marrow cells and neuroinflammation in hypertension. Circ Res. 117:2 (2015), 178–191.
122. Wei, S.G., Yu, Y., Zhang, Z.H., Felder, R.B., Proinflammatory cytokines upregulate sympathoexcitatory mechanisms in the subfornical organ of the rat. Hypertension 65:5 (2015), 1126–1133.
123. Jun, J.Y., Zubcevic, J., Qi, Y., Afzal, A., Carvajal, J.M., Thinschmidt, J.S., Grant, M.B., Mocco, J., Raizada, M.K., Brain-mediated dysregulation of the bone marrow activity in angiotensin II-induced hypertension. Hypertension 60:5 (2012), 1316–1323.
124. Zubcevic, J., Jun, J.Y., Kim, S., Perez, P.D., Afzal, A., Shan, Z., Li, W., Santisteban, M.M., Yuan, W., Febo, M., Mocco, J., Feng, Y., Scott, E., Baekey, D.M., Raizada, M.K., Altered inflammatory response is associated with an impaired autonomic input to the bone marrow in the spontaneously hypertensive rat. Hypertension 63:3 (2014), 542–550.
125. Schwab, J.M., Chiang, N., Arita, M., Serhan, C.N., Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature. 447:7146 (2007), 869–874.
126. Serhan, C.N., Pro-resolving lipid mediators are leads for resolution physiology. Nature. 510:7503 (2014), 92–101.
127. Serhan, C.N., Chiang, N., Dalli, J., The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. Semin Immunol. 27:3 (2015), 200–215.
128. Fredman, G., Tabas, I., Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. Am J Pathol. 187:6 (2017), 1211–1221.
129. Levy, B.D., Clish, C.B., Schmidt, B., Gronert, K., Serhan, C.N., Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2:7 (2001), 612–619.
130. Serhan, C.N., Clish, C.B., Brannon, J., Colgan, S.P., Chiang, N., Gronert, K., Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 192:8 (2000), 1197–1204.
131. Serhan, C.N., Hong, S., Gronert, K., Colgan, S.P., Devchand, P.R., Mirick, G., Moussignac, R.L., Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 196:8 (2002), 1025–1037.
132. Perretti, M., Chiang, N., La, M., Fierro, I.M., Marullo, S., Getting, S.J., Solito, E., Serhan, C.N., Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med. 8:11 (2002), 1296–1302.
133. Wallace, J.L., Ianaro, A., Flannigan, K.L., Cirino, G., Gaseous mediators in resolution of inflammation. Semin Immunol. 27:3 (2015), 227–233.
134. Shinohara, M., Serhan, C.N., Novel Endogenous Proresolving Molecules: Essential Fatty Acid-Derived and Gaseous Mediators in the Resolution of Inflammation. J Atheroscler Thromb. 23:6 (2016), 655–664.
135. Cronstein, B.N., Montesinos, M.C., Weissmann, G., Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci U S A. 96:11 (1999), 6377–6381.
136. Brinkmann, V., Reichard, U., Goosmann, C., Fauler, B., Uhlemann, Y., Weiss, D.S., Weinrauch, Y., Zychlinsky, A., Neutrophil extracellular traps kill bacteria. Science 303:5663 (2004), 1532–1535.
137. Gagliani, N., Amezcua Vesely, M.C., Iseppon, A., Brockmann, L., Xu, H., Palm, N.W., de Zoete, M.R., Licona-Limon, P., Paiva, R.S., Ching, T., Weaver, C., Zi, X., Pan, X., Fan, R., Garmire, L.X., Cotton, M.J., Drier, Y., Bernstein, B., Geginat, J., Stockinger, B., Esplugues, E., Huber, S., Flavell, R.A., Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 523:7559 (2015), 221–225.
138. Joffre, C., Gregoire, S., De Smedt, V., Acar, N., Bretillon, L., Nadjar, A., Laye, S., Modulation of brain PUFA content in different experimental models of mice. Prostaglandins Leukot Essent Fatty Acids 114 (2016), 1–10.
139. Kitajka, K., Sinclair, A.J., Weisinger, R.S., Weisinger, H.S., Mathai, M., Jayasooriya, A.P., Halver, J.E., Puskas, L.G., Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci U S A. 101:30 (2004), 10931–10936.
140. Buckley, C.D., Gilroy, D.W., Serhan, C.N., Stockinger, B., Tak, P.P., The resolution of inflammation. Nat Rev Immunol. 13:1 (2013), 59–66.
141. Calder, P.C., Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta 1851:4 (2015), 469–484.
142. Di Marzo, V., Stella, N., Zimmer, A., Endocannabinoid signalling and the deteriorating brain. Nat Rev Neurosci. 16:1 (2015), 30–42.
143. Lukiw, W.J., Bazan, N.G., Neuroinflammatory signaling upregulation in Alzheimer's disease. Neurochem Res. 25:9-10 (2000), 1173–1184.
144. Witkamp, R., Fatty acids, endocannabinoids and inflammation. Eur J Pharmacol. 785 (2016), 96–107.
145. Bazinet, R.P., Laye, S., Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci. 15:12 (2014), 771–785.
146. Serhan, C.N., Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 25 (2007), 101–137.
147. Serhan, C.N., Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution. Prostaglandins Leukot Essent Fatty Acids 73:3-4 (2005), 141–162.
148. Khan, S.I., Shihata, W.A., Andrews, K.L., Lee, M.K.S., Moore, X.L., Jefferis, A.M., Vinh, A., Gaspari, T., Dragoljevic, D., Jennings, G.L., Murphy, A.J., Chin-Dusting, J.P.F., Effects of high- and low-dose aspirin on adaptive immunity and hypertension in the stroke-prone spontaneously hypertensive rat. FASEB J. 33:1 (2019), 1510–1521.
149. Bally, M., Dendukuri, N., Rich, B., Nadeau, L., Helin-Salmivaara, A., Garbe, E., Brophy, J.M., Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ, 357, 2017, j1909.
150. Cheng, H.F., Harris, R.C., Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 11:14 (2005), 1795–1804.
151. Rovati, G.E., Sala, A., Capra, V., Dahlen, S.E., Folco, G., Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends Pharmacol Sci. 31:3 (2010), 102–107.
152. Qi, Z., Hao, C.M., Langenbach, R.I., Breyer, R.M., Redha, R., Morrow, J.D., Breyer, M.D., Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 110:1 (2002), 61–69.
153. Gilroy, D.W., Colville-Nash, P.R., Willis, D., Chivers, J., Paul-Clark, M.J., Willoughby, D.A., Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med. 5:6 (1999), 698–701.
154. Corminboeuf, O., Leroy, X., FPR2/ALXR agonists and the resolution of inflammation. J Med Chem. 58:2 (2015), 537–559.
155. Bayorh, M.A., Williams, E.F., Ogbolu, E.C., Walker, C.E., Manor, E.L., Brown, L.G., Chenault, V.M., Effects of MaxEPA on salt-induced hypertension: relationship to [3H]nitrobenzylthioinosine binding sites. Clin Exp Hypertens. 18:1 (1996), 37–49.
156. Bellenger-Germain, S., Poisson, J.P., Narce, M., Antihypertensive effects of a dietary unsaturated FA mixture in spontaneously hypertensive rats. Lipids. 37:6 (2002), 561–567.
157. Bond, V., Ordor, O., Bruckner, G., Webb, P., Kotchen, T., Tearney, R.J., Adams, R.G., Effects of dietary fish oil or pectin on blood pressure and lipid metabolism in the DOCA-salt hypertensive rat. J Nutr. 119:5 (1989), 813–817.
158. Hui, R., St-Louis, J., Falardeau, P., Antihypertensive properties of linoleic acid and fish oil omega-3 fatty acids independent of the prostaglandin system. Am J Hypertens. 2:8 (1989), 610–617.
159. Mozaffarian, D., Fish, n-3 fatty acids, and cardiovascular haemodynamics. J Cardiovasc Med (Hagerstown)(8 Suppl. 1), 2007, S23–S26.
160. Schoene, N.W., Fiore, D., Effect of a diet containing fish oil on blood pressure in spontaneously hypertensive rats. Prog Lipid Res. 20 (1981), 569–570.
161. Yin, K., Chu, Z.M., Beilin, L.J., Blood pressure and vascular reactivity changes in spontaneously hypertensive rats fed fish oil. Br J Pharmacol. 102:4 (1991), 991–997.
162. Yin, K., Chu, Z.M., Beilin, L.J., Effect of fish oil feeding on blood pressure and vascular reactivity in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 17:3 (1990), 235–239.
163. Rousseau-Ralliard, D., Moreau, D., Guilland, J.C., Raederstorff, D., Grynberg, A., Docosahexaenoic acid, but not eicosapentaenoic acid, lowers ambulatory blood pressure and shortens interval QT in spontaneously hypertensive rats in vivo. Prostaglandins Leukot Essent Fatty Acids 80:5-6 (2009), 269–277.
164. van den Elsen, L.W., Spijkers, L.J., van den Akker, R.F., van Winssen, A.M., Balvers, M., Wijesinghe, D.S., Chalfant, C.E., Garssen, J., Willemsen, L.E., Alewijnse, A.E., Peters, S.L., Dietary fish oil improves endothelial function and lowers blood pressure via suppression of sphingolipid-mediated contractions in spontaneously hypertensive rats. J Hypertens. 32:5 (2014), 1050–1058 discussion 1058.
165. Huang, Y.P., Jin, H.Y., Yu, H.P., Inhibitory effects of alpha-lipoic acid on oxidative stress in the rostral ventrolateral medulla in rats with salt-induced hypertension. Int J Mol Med. 39:2 (2017), 430–436.
166. Mano, M.T., Bexis, S., Abeywardena, M.Y., McMurchie, E.J., King, R.A., Smith, R.M., Head, R.J., Fish oils modulate blood pressure and vascular contractility in the rat and vascular contractility in the primate. Blood Press. 4:3 (1995), 177–186.
167. Armitage, J.A., Pearce, A.D., Sinclair, A.J., Vingrys, A.J., Weisinger, R.S., Weisinger, H.S., Increased blood pressure later in life may be associated with perinatal n-3 fatty acid deficiency. Lipids. 38:4 (2003), 459–464.
168. Weisinger, H.S., Armitage, J.A., Sinclair, A.J., Vingrys, A.J., Burns, P.L., Weisinger, R.S., Perinatal omega-3 fatty acid deficiency affects blood pressure later in life. Nat Med. 7:3 (2001), 258–259.
169. Campbell, D.J., Rong, P., Kladis, A., Rees, B., Ganten, D., Skinner, S.L., Angiotensin and bradykinin peptides in the TGR(mRen-2)27 rat. Hypertension 25:5 (1995), 1014–1020.
170. Callahan, M.F., Li, P., Ferrario, C.M., Ganten, D., Morris, M., Salt-sensitive hypertension in (mREN-2)27 transgenic rats. Hypertension 27:3 Pt 2 (1996), 573–577.
171. Begg, D.P., Puskas, L.G., Kitajka, K., Menesi, D., Allen, A.M., Li, D., Mathai, M.L., Shi, J.R., Sinclair, A.J., Weisinger, R.S., Hypothalamic gene expression in omega-3 PUFA-deficient male rats before, and following, development of hypertension. Hypertens Res. 35:4 (2012), 381–387.
172. Jayasooriya, A.P., Begg, D.P., Chen, N., Mathai, M.L., Sinclair, A.J., Wilkinson-Berka, J., Wark, J.D., Weisinger, H.S., Weisinger, R.S., Omega-3 polyunsaturated fatty acid supplementation reduces hypertension in TGR(mRen-2)27 rats. Prostaglandins Leukot Essent Fatty Acids 78:1 (2008), 67–72.
173. Adler, N., Schoeniger, A., Fuhrmann, H., Polyunsaturated fatty acids influence inflammatory markers in a cellular model for canine osteoarthritis. J Anim Physiol Anim Nutr (Berl). 102:2 (2018), e623–e632.
174. Faber, J., Berkhout, M., Fiedler, U., Avlar, M., Witteman, B.J., Vos, A.P., Henke, M., Garssen, J., van Helvoort, A., Otten, M.H., Arends, J., Rapid EPA and DHA incorporation and reduced PGE2 levels after one week intervention with a medical food in cancer patients receiving radiotherapy, a randomized trial. Clin Nutr. 32:3 (2013), 338–345.
175. Langerhuus, S.N., Tonnesen, E.K., Jensen, K.H., Damgaard, B.M., Halekoh, U., Lauridsen, C., Effects of dietary n-3 and n-6 fatty acids on clinical outcome in a porcine model on post-operative infection. Br J Nutr. 107:5 (2012), 735–743.
176. Mocellin, M.C., Pastore e Silva Jde, A., Camargo Cde, Q., Fabre, M.E., Gevaerd, S., Naliwaiko, K., Moreno, Y.M., Nunes, E.A., Trindade, E.B., Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients. Lipids 48:9 (2013), 879–888.
177. Ramirez-Ramirez, V., Macias-Islas, M.A., Ortiz, G.G., Pacheco-Moises, F., Torres-Sanchez, E.D., Sorto-Gomez, T.E., Cruz-Ramos, J.A., Orozco-Avina, G., Celis de la Rosa, A.J., Efficacy of fish oil on serum of TNF alpha, IL-1 beta, and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b. Oxid Med Cell Longev., 2013, 2013, 709493.
178. Siriwardhana, N., Kalupahana, N.S., Fletcher, S., Xin, W., Claycombe, K.J., Quignard-Boulange, A., Zhao, L., Saxton, A.M., Moustaid-Moussa, N., n-3 and n-6 polyunsaturated fatty acids differentially regulate adipose angiotensinogen and other inflammatory adipokines in part via NF-kappaB-dependent mechanisms. J Nutr Biochem. 23:12 (2012), 1661–1667.
179. Takase, O., Hishikawa, K., Kamiura, N., Nakakuki, M., Kawano, H., Mizuguchi, K., Fujita, T., Eicosapentaenoic acid regulates IkappaBalpha and prevents tubulointerstitial injury in kidney. Eur J Pharmacol. 669:1-3 (2011), 128–135.
180. Kumar, K.V., Das, U.N., Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. Proc Soc Exp Biol Med. 214:4 (1997), 374–379.
181. Cicero, A.F., Ertek, S., Borghi, C., Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. Curr Vasc Pharmacol. 7:3 (2009), 330–337.
182. De Caterina, R., Liao, J.K., Libby, P., Fatty acid modulation of endothelial activation. Am J Clin Nutr. 71:1 Suppl (2000), 213S–223S.
183. Juan, H., Sametz, W., Vasoconstriction induced by noradrenaline and angiotensin II is antagonized by eicosapentaenoic acid independent of formation of trienoic eicosanoids. Naunyn Schmiedebergs Arch Pharmacol. 332:3 (1986), 288–292.
184. Juan, H., Sutter, D., Sametz, W., Influence of eicosapentaenoic acid on noradrenaline and angiotensin-induced contractions of the rabbit aorta: mode of action. Prog Clin Biol Res. 242 (1987), 57–62.
185. Polizio, A.H., Gironacci, M.M., Tomaro, M.L., Pena, C., Angiotensin-(1-7) blocks the angiotensin II-stimulated superoxide production. Pharmacol Res. 56:1 (2007), 86–90.
186. Nascimento-Silva, V., Arruda, M.A., Barja-Fidalgo, C., Fierro, I.M., Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: a novel antioxidative mechanism. Thromb Haemost. 97:1 (2007), 88–98.
187. Imig, J.D., Zou, A.P., Stec, D.E., Harder, D.R., Falck, J.R., Roman, R.J., Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol. 270:1 Pt 2 (1996), R217–R227.
188. Gehling, U.M., Ergun, S., Schumacher, U., Wagener, C., Pantel, K., Otte, M., Schuch, G., Schafhausen, P., Mende, T., Kilic, N., Kluge, K., Schafer, B., Hossfeld, D.K., Fiedler, W., In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95:10 (2000), 3106–3112.
189. Cvetkovic, B., Sigmund, C.D., Understanding hypertension through genetic manipulation in mice. Kidney Int. 57:3 (2000), 863–874.
190. Cheng, J., Garcia, V., Ding, Y., Wu, C.C., Thakar, K., Falck, J.R., Ramu, E., Schwartzman, M.L., Induction of angiotensin-converting enzyme and activation of the renin-angiotensin system contribute to 20-hydroxyeicosatetraenoic acid-mediated endothelial dysfunction. Arterioscler Thromb Vasc Biol. 32:8 (2012), 1917–1924.
191. Sacerdoti, D., Escalante, B., Abraham, N.G., McGiff, J.C., Levere, R.D., Schwartzman, M.L., Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 243:4889 (1989), 388–390.
192. Dunn, K.M., Renic, M., Flasch, A.K., Harder, D.R., Falck, J., Roman, R.J., Elevated production of 20-HETE in the cerebral vasculature contributes to severity of ischemic stroke and oxidative stress in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol. 295:6 (2008), H2455–2465.
193. Garcia, V., Joseph, G., Shkolnik, B., Ding, Y., Zhang, F.F., Gotlinger, K., Falck, J.R., Dakarapu, R., Capdevila, J.H., Bernstein, K.E., Schwartzman, M.L., Angiotensin II receptor blockade or deletion of vascular endothelial ACE does not prevent vascular dysfunction and remodeling in 20-HETE-dependent hypertension. Am J Physiol Regul Integr Comp Physiol. 309:1 (2015), R71–78.
194. Decker, Y., McBean, G., Godson, C., Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells. Am J Physiol Cell Physiol. 296:6 (2009), C1420–C1427.
195. Chen, S., Zhang, H., Pu, H., Wang, G., Li, W., Leak, R.K., Chen, J., Liou, A.K., Hu, X., n-3 PUFA supplementation benefits microglial responses to myelin pathology. Sci Rep., 4, 2014, 7458.
196. Chhor, V., Le Charpentier, T., Lebon, S., Ore, M.V., Celador, I.L., Josserand, J., Degos, V., Jacotot, E., Hagberg, H., Savman, K., Mallard, C., Gressens, P., Fleiss, B., Characterization of phenotype markers and neuronotoxic potential of polarised primary microglia in vitro. Brain Behav Immun. 32 (2013), 70–85.
197. Ebert, S., Weigelt, K., Walczak, Y., Drobnik, W., Mauerer, R., Hume, D.A., Weber, B.H., Langmann, T., Docosahexaenoic acid attenuates microglial activation and delays early retinal degeneration. J Neurochem. 110:6 (2009), 1863–1875.
198. Hjorth, E., Zhu, M., Toro, V.C., Vedin, I., Palmblad, J., Cederholm, T., Freund-Levi, Y., Faxen-Irving, G., Wahlund, L.O., Basun, H., Eriksdotter, M., Schultzberg, M., Omega-3 fatty acids enhance phagocytosis of Alzheimer's disease-related amyloid-beta42 by human microglia and decrease inflammatory markers. J Alzheimers Dis. 35:4 (2013), 697–713.
199. Moon, D.O., Kim, K.C., Jin, C.Y., Han, M.H., Park, C., Lee, K.J., Park, Y.M., Choi, Y.H., Kim, G.Y., Inhibitory effects of eicosapentaenoic acid on lipopolysaccharide-induced activation in BV2 microglia. Int Immunopharmacol. 7:2 (2007), 222–229.
200. Trepanier, M.O., Hopperton, K.E., Orr, S.K., Bazinet, R.P., N-3 polyunsaturated fatty acids in animal models with neuroinflammation: An update. Eur J Pharmacol. 785 (2016), 187–206.
201. Antonietta Ajmone-Cat, M., Lavinia Salvatori, M., De Simone, R., Mancini, M., Biagioni, S., Bernardo, A., Cacci, E., Minghetti, L., Docosahexaenoic acid modulates inflammatory and antineurogenic functions of activated microglial cells. J Neurosci Res. 90:3 (2012), 575–587.
202. Corsi, L., Dongmo, B.M., Avallone, R., Supplementation of omega 3 fatty acids improves oxidative stress in activated BV2 microglial cell line. Int J Food Sci Nutr. 66:3 (2015), 293–299.
203. Lu, D.Y., Tsao, Y.Y., Leung, Y.M., Su, K.P., Docosahexaenoic acid suppresses neuroinflammatory responses and induces heme oxygenase-1 expression in BV-2 microglia: implications of antidepressant effects for omega-3 fatty acids. Neuropsychopharmacology 35:11 (2010), 2238–2248.
204. Pettit, L.K., Varsanyi, C., Tadros, J., Vassiliou, E., Modulating the inflammatory properties of activated microglia with Docosahexaenoic acid and Aspirin. Lipids Health Dis., 12, 2013, 16.
205. Zendedel, A., Habib, P., Dang, J., Lammerding, L., Hoffmann, S., Beyer, C., Slowik, A., Omega-3 polyunsaturated fatty acids ameliorate neuroinflammation and mitigate ischemic stroke damage through interactions with astrocytes and microglia. J Neuroimmunol. 278 (2015), 200–211.
206. Liuzzi, G.M., Latronico, T., Rossano, R., Viggiani, S., Fasano, A., Riccio, P., Inhibitory effect of polyunsaturated fatty acids on MMP-9 release from microglial cells—implications for complementary multiple sclerosis treatment. Neurochem Res. 32:12 (2007), 2184–2193.
207. De Smedt-Peyrusse, V., Sargueil, F., Moranis, A., Harizi, H., Mongrand, S., Laye, S., Docosahexaenoic acid prevents lipopolysaccharide-induced cytokine production in microglial cells by inhibiting lipopolysaccharide receptor presentation but not its membrane subdomain localization. J Neurochem. 105:2 (2008), 296–307.
208. Chang, P.K., Khatchadourian, A., McKinney, R.A., Maysinger, D., Docosahexaenoic acid (DHA): a modulator of microglia activity and dendritic spine morphology. J Neuroinflammation., 12, 2015, 34.
209. Ma, Q.L., Yang, F., Rosario, E.R., Ubeda, O.J., Beech, W., Gant, D.J., Chen, P.P., Hudspeth, B., Chen, C., Zhao, Y., Vinters, H.V., Frautschy, S.A., Cole, G.M., Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci. 29:28 (2009), 9078–9089.
210. Wu, Y., Wang, Y.P., Guo, P., Ye, X.H., Wang, J., Yuan, S.Y., Yao, S.L., Shang, Y., A lipoxin A4 analog ameliorates blood-brain barrier dysfunction and reduces MMP-9 expression in a rat model of focal cerebral ischemia-reperfusion injury. J Mol Neurosci. 46:3 (2012), 483–491.
211. Feng, Q., Wang, Y.I., Yang, Y., Neuroprotective effect of interleukin-6 in a rat model of cerebral ischemia. Exp Ther Med. 9:5 (2015), 1695–1701.
212. Hawkins, K.E., DeMars, K.M., Alexander, J.C., de Leon, L.G., Pacheco, S.C., Graves, C., Yang, C., McCrea, A.O., Frankowski, J.C., Garrett, T.J., Febo, M., Candelario-Jalil, E., Targeting resolution of neuroinflammation after ischemic stroke with a lipoxin A4 analog: Protective mechanisms and long-term effects on neurological recovery. Brain Behav., 7(5), 2017, e00688.
213. Mowry, F.E., Silva-Cutini, M.C., Peaden, S.C., Biancardi, V.C., Angiotensin II-Mediated AT1R-TLR4 Crosstalk Promotes Blood-Brain Barrier Disruption, Microglial Activation, and Sympathoexcitation in Hypertension. The FASEB Journal., 33(1 supplement), 2019 859.856–859.856.
214. Krishnamoorthy, S., Recchiuti, A., Chiang, N., Yacoubian, S., Lee, C.H., Yang, R., Petasis, N.A., Serhan, C.N., Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A. 107:4 (2010), 1660–1665.
215. Arita, M., Bianchini, F., Aliberti, J., Sher, A., Chiang, N., Hong, S., Yang, R., Petasis, N.A., Serhan, C.N., Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 201:5 (2005), 713–722.
216. Samson, M., Edinger, A.L., Stordeur, P., Rucker, J., Verhasselt, V., Sharron, M., Govaerts, C., Mollereau, C., Vassart, G., Doms, R.W., Parmentier, M., ChemR23, a putative chemoattractant receptor, is expressed in monocyte-derived dendritic cells and macrophages and is a coreceptor for SIV and some primary HIV-1 strains. Eur J Immunol. 28:5 (1998), 1689–1700.
217. Xu, Z.Z., Berta, T., Ji, R.R., Resolvin E1 inhibits neuropathic pain and spinal cord microglial activation following peripheral nerve injury. J Neuroimmune Pharmacol. 8:1 (2013), 37–41.
218. Harrison, J.L., Rowe, R.K., Ellis, T.W., Yee, N.S., O'Hara, B.F., Adelson, P.D., Lifshitz, J., Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse. Brain Behav Immun. 47 (2015), 131–140.
219. Rey, C., Nadjar, A., Buaud, B., Vaysse, C., Aubert, A., Pallet, V., Laye, S., Joffre, C., Resolvin D1 and E1 promote resolution of inflammation in microglial cells in vitro. Brain Behav Immun. 55 (2016), 249–259.
220. Hong, S., Gronert, K., Devchand, P.R., Moussignac, R.L., Serhan, C.N., Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem. 278:17 (2003), 14677–14687.
221. Lukiw, W.J., Cui, J.G., Marcheselli, V.L., Bodker, M., Botkjaer, A., Gotlinger, K., Serhan, C.N., Bazan, N.G., A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 115:10 (2005), 2774–2783.
222. Marcheselli, V.L., Hong, S., Lukiw, W.J., Tian, X.H., Gronert, K., Musto, A., Hardy, M., Gimenez, J.M., Chiang, N., Serhan, C.N., Bazan, N.G., Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem. 278:44 (2003), 43807–43817.
223. Marcheselli, V.L., Mukherjee, P.K., Arita, M., Hong, S., Antony, R., Sheets, K., Winkler, J.W., Petasis, N.A., Serhan, C.N., Bazan, N.G., Neuroprotectin D1/protectin D1 stereoselective and specific binding with human retinal pigment epithelial cells and neutrophils. Prostaglandins Leukot Essent Fatty Acids 82:1 (2010), 27–34.
224. Orr, S.K., Palumbo, S., Bosetti, F., Mount, H.T., Kang, J.X., Greenwood, C.E., Ma, D.W., Serhan, C.N., Bazinet, R.P., Unesterified docosahexaenoic acid is protective in neuroinflammation. J Neurochem. 127:3 (2013), 378–393.
225. Orr, S.K., Trepanier, M.O., Bazinet, R.P., n-3 Polyunsaturated fatty acids in animal models with neuroinflammation. Prostaglandins Leukot Essent Fatty Acids 88:1 (2013), 97–103.
226. Park, T., Chen, H., Kevala, K., Lee, J.W., Kim, H.Y., N-Docosahexaenoylethanolamine ameliorates LPS-induced neuroinflammation via cAMP/PKA-dependent signaling. J Neuroinflammation., 13(1), 2016, 284.
227. Meijerink, J., Plastina, P., Vincken, J.P., Poland, M., Attya, M., Balvers, M., Gruppen, H., Gabriele, B., Witkamp, R.F., The ethanolamide metabolite of DHA, docosahexaenoylethanolamine, shows immunomodulating effects in mouse peritoneal and RAW264.7 macrophages: evidence for a new link between fish oil and inflammation. Br J Nutr. 105:12 (2011), 1798–1807.
228. Meijerink, J., Poland, M., Balvers, M.G., Plastina, P., Lute, C., Dwarkasing, J., van Norren, K., Witkamp, R.F., Inhibition of COX-2-mediated eicosanoid production plays a major role in the anti-inflammatory effects of the endocannabinoid N-docosahexaenoylethanolamine (DHEA) in macrophages. Br J Pharmacol. 172:1 (2015), 24–37.
229. Kuda, O., Bioactive metabolites of docosahexaenoic acid. Biochimie 136 (2017), 12–20.
230. Shinohara, M., Mirakaj, V., Serhan, C.N., Functional Metabolomics Reveals Novel Active Products in the DHA Metabolome. Front Immunol., 3, 2012, 81.
231. Yang, R., Fredman, G., Krishnamoorthy, S., Agrawal, N., Irimia, D., Piomelli, D., Serhan, C.N., Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signals. J Biol Chem. 286:36 (2011), 31532–31541.
232. Piomelli, D., Sasso, O., Peripheral gating of pain signals by endogenous lipid mediators. Nat Neurosci. 17:2 (2014), 164–174.
233. Stella, N., Endocannabinoid signaling in microglial cells. Neuropharmacology(56 Suppl 1), 2009, 244–253.
234. Ibrahim, B.M., Abdel-Rahman, A.A., Role of brainstem GABAergic signaling in central cannabinoid receptor evoked sympathoexcitation and pressor responses in conscious rats. Brain Res. 1414 (2011), 1–9.
235. Brozoski, D.T., Dean, C., Hopp, F.A., Seagard, J.L., Uptake blockade of endocannabinoids in the NTS modulates baroreflex-evoked sympathoinhibition. Brain Res. 1059:2 (2005), 197–202.
236. Seagard, J.L., Dean, C., Patel, S., Rademacher, D.J., Hopp, F.A., Schmeling, W.T., Hillard, C.J., Anandamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition. Am J Physiol Heart Circ Physiol. 286:3 (2004), H992–H1000.
237. Schaich, C.L., Shaltout, H.A., Brosnihan, K.B., Howlett, A.C., Diz, D.I., Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats. Physiol Rep., 2(8), 2014.
238. Wang, T., Li, G.Q., Zhang, H.P., Zhang, Y., Li, Q., Overactivation of cannabinoid receptor type 1 in rostral ventrolateral medulla promotes cardiovascular responses in spontaneously hypertensive rats. J Hypertens. 35:3 (2017), 538–545.
239. Maccarrone, M., Endocannabinoid signaling and neuroinflammatory diseases. Curr Pharm Des. 14:23 (2008), 2252–2253.
240. Mazier, W., Saucisse, N., Gatta-Cherifi, B., Cota, D., The Endocannabinoid System: Pivotal Orchestrator of Obesity and Metabolic Disease. Trends Endocrinol Metab. 26:10 (2015), 524–537.
241. Steffens, S., Pacher, P., The activated endocannabinoid system in atherosclerosis: driving force or protective mechanism?. Curr Drug Targets 16:4 (2015), 334–341.
242. Velasco, G., Sanchez, C., Guzman, M., Endocannabinoids and Cancer. Handb Exp Pharmacol. 231 (2015), 449–472.
243. Impellizzeri, D., Cordaro, M., Bruschetta, G., Siracusa, R., Crupi, R., Esposito, E., Cuzzocrea, S., N-Palmitoylethanolamine-Oxazoline as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury. J Neurotrauma. 34:18 (2017), 2609–2623.
244. Impellizzeri, D., Siracusa, R., Cordaro, M., Crupi, R., Peritore, A.F., Gugliandolo, E., D'Amico, R., Petrosino, S., Evangelista, M., Di Paola, R., Cuzzocrea, S., N-Palmitoylethanolamine-oxazoline (PEA-OXA): A new therapeutic strategy to reduce neuroinflammation, oxidative stress associated to vascular dementia in an experimental model of repeated bilateral common carotid arteries occlusion. Neurobiol Dis., 2019.
245. Mecha, M., Carrillo-Salinas, F.J., Feliu, A., Mestre, L., Guaza, C., Microglia activation states and cannabinoid system: Therapeutic implications. Pharmacol Ther. 166 (2016), 40–55.
246. Mecha, M., Feliu, A., Carrillo-Salinas, F.J., Rueda-Zubiaurre, A., Ortega-Gutierrez, S., de Sola, R.G., Guaza, C., Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav Immun. 49 (2015), 233–245.
247. Skaper, S.D., Facci, L., Barbierato, M., Zusso, M., Bruschetta, G., Impellizzeri, D., Cuzzocrea, S., Giusti, P., N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution. Mol Neurobiol. 52:2 (2015), 1034–1042.
248. Aizpurua-Olaizola, O., Elezgarai, I., Rico-Barrio, I., Zarandona, I., Etxebarria, N., Usobiaga, A., Targeting the endocannabinoid system: future therapeutic strategies. Drug Discov Today. 22:1 (2017), 105–110.
249. Chiurchiu, V., Cencioni, M.T., Bisicchia, E., De Bardi, M., Gasperini, C., Borsellino, G., Centonze, D., Battistini, L., Maccarrone, M., Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis. Ann Neurol. 73:5 (2013), 626–636.
250. Chiurchiu, V., Lanuti, M., Catanzaro, G., Fezza, F., Rapino, C., Maccarrone, M., Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. Atherosclerosis 233:1 (2014), 55–63.
251. Lipina, C., Hundal, H.S., Modulation of cellular redox homeostasis by the endocannabinoid system. Open Biol., 6(4), 2016, 150276.
252. Cabral, G.A., Ferreira, G.A., Jamerson, M.J., Endocannabinoids and the Immune System in Health and Disease. Handb Exp Pharmacol. 231 (2015), 185–211.
253. McCollum, L.T., Gallagher, P.E., Ann Tallant, E., Angiotensin-(1-7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1. Am J Physiol Heart Circ Physiol. 302:3 (2012), H801–H810.
254. Santos, R.A., Angiotensin-(1-7). Hypertension 63:6 (2014), 1138–1147.
255. Lautner, R.Q., Villela, D.C., Fraga-Silva, R.A., Silva, N., Verano-Braga, T., Costa-Fraga, F., Jankowski, J., Jankowski, V., Sousa, F., Alzamora, A., Soares, E., Barbosa, C., Kjeldsen, F., Oliveira, A., Braga, J., Savergnini, S., Maia, G., Peluso, A.B., Passos-Silva, D., Ferreira, A., Alves, F., Martins, A., Raizada, M., Paula, R., Motta-Santos, D., Klempin, F., Pimenta, A., Alenina, N., Sinisterra, R., Bader, M., Campagnole-Santos, M.J., Santos, R.A., Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res. 112:8 (2013), 1104–1111.
256. Feng, Y., Yue, X., Xia, H., Bindom, S.M., Hickman, P.J., Filipeanu, C.M., Wu, G., Lazartigues, E., Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res. 102:6 (2008), 729–736.
257. Xia, H., de Queiroz, T.M., Sriramula, S., Feng, Y., Johnson, T., Mungrue, I.N., Lazartigues, E., Brain ACE2 overexpression reduces DOCA-salt hypertension independently of endoplasmic reticulum stress. Am J Physiol Regul Integr Comp Physiol. 308:5 (2015), R370–R378.
258. Yamazato, M., Yamazato, Y., Sun, C., Diez-Freire, C., Raizada, M.K., Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension 49:4 (2007), 926–931.
259. Deshotels, M.R., Xia, H., Sriramula, S., Lazartigues, E., Filipeanu, C.M., Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism. Hypertension 64:6 (2014), 1368–1375.
260. Xia, H., Feng, Y., Obr, T.D., Hickman, P.J., Lazartigues, E., Angiotensin II type 1 receptor-mediated reduction of angiotensin-converting enzyme 2 activity in the brain impairs baroreflex function in hypertensive mice. Hypertension 53:2 (2009), 210–216.
261. Yu, X.J., Miao, Y.W., Li, H.B., Su, Q., Liu, K.L., Fu, L.Y., Hou, Y.K., Shi, X.L., Li, Y., Mu, J.J., Chen, W.S., Cui, W., Zhu, G.Q., Ebenezer, P.J., Francis, J., Kang, Y.M., Blockade of Endogenous Angiotensin-(1-7) in Hypothalamic Paraventricular Nucleus Attenuates High Salt-Induced Sympathoexcitation and Hypertension. Neurosci Bull., 2018.
262. Zhou, L.M., Shi, Z., Gao, J., Han, Y., Yuan, N., Gao, X.Y., Zhu, G.Q., Angiotensin-(1-7) and angiotension II in the rostral ventrolateral medulla modulate the cardiac sympathetic afferent reflex and sympathetic activity in rats. Pflugers Arch. 459:5 (2010), 681–688.
263. da Silveira, K.D., Coelho, F.M., Vieira, A.T., Sachs, D., Barroso, L.C., Costa, V.V., Bretas, T.L., Bader, M., de Sousa, L.P., da Silva, T.A., dos Santos, R.A., Simoes e Silva, A.C., Teixeira, M.M., Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol. 185:9 (2010), 5569–5576.
264. Magalhaes, G.S., Rodrigues-Machado, M.G., Motta-Santos, D., Alenina, N., Bader, M., Santos, R.A., Barcelos, L.S., Campagnole-Santos, M.J., Chronic allergic pulmonary inflammation is aggravated in angiotensin-(1-7) Mas receptor knockout mice. Am J Physiol Lung Cell Mol Physiol. 311:6 (2016), L1141–L1148.
265. Feltenberger, J.D., Andrade, J.M., Paraiso, A., Barros, L.O., Filho, A.B., Sinisterra, R.D., Sousa, F.B., Guimaraes, A.L., de Paula, A.M., Campagnole-Santos, M.J., Qureshi, M., dos Santos, R.A., Santos, S.H., Oral formulation of angiotensin-(1-7) improves lipid metabolism and prevents high-fat diet-induced hepatic steatosis and inflammation in mice. Hypertension. 62:2 (2013), 324–330.
266. Khajah, M.A., Fateel, M.M., Ananthalakshmi, K.V., Luqmani, Y.A., Anti-Inflammatory Action of Angiotensin 1-7 in Experimental Colitis. PLoS One, 11(3), 2016, e0150861.
267. Meng, Y., Li, T., Zhou, G.S., Chen, Y., Yu, C.H., Pang, M.X., Li, W., Li, Y., Zhang, W.Y., Li, X., The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway. Antioxid Redox Signal. 22:3 (2015), 241–258.
268. Li, W., Li, J., Hao, P., Chen, W., Meng, X., Li, H., Zhang, Y., Zhang, C., Yang, J., Imbalance between angiotensin II and angiotensin-(1-7) in human coronary atherosclerosis. J Renin Angiotensin Aldosterone Syst., 17(3), 2016.
269. Li, Y., Zeng, Z., Cao, Y., Liu, Y., Ping, F., Liang, M., Xue, Y., Xi, C., Zhou, M., Jiang, W., Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-kappaB signaling pathways. Sci Rep., 6, 2016, 27911.
270. Magalhaes, G.S., Rodrigues-Machado, M.G., Motta-Santos, D., Silva, A.R., Caliari, M.V., Prata, L.O., Abreu, S.C., Rocco, P.R., Barcelos, L.S., Santos, R.A., Campagnole-Santos, M.J., Angiotensin-(1-7) attenuates airway remodelling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol. 172:9 (2015), 2330–2342.
271. Rodrigues-Machado, M.G., Magalhaes, G.S., Cardoso, J.A., Kangussu, L.M., Murari, A., Caliari, M.V., Oliveira, M.L., Cara, D.C., Noviello, M.L., Marques, F.D., Pereira, J.M., Lautner, R.Q., Santos, R.A., Campagnole-Santos, M.J., AVE 0991, a non-peptide mimic of angiotensin-(1-7) effects, attenuates pulmonary remodelling in a model of chronic asthma. Br J Pharmacol. 170:4 (2013), 835–846.
272. Shenoy, V., Ferreira, A.J., Qi, Y., Fraga-Silva, R.A., Diez-Freire, C., Dooies, A., Jun, J.Y., Sriramula, S., Mariappan, N., Pourang, D., Venugopal, C.S., Francis, J., Reudelhuber, T., Santos, R.A., Patel, J.M., Raizada, M.K., Katovich, M.J., The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 182:8 (2010), 1065–1072.
273. Magalhaes, G.S., Barroso, L.C., Reis, A.C., Rodrigues-Machado, M.G., Gregorio, J.F., Motta-Santos, D., Oliveira, A.C., Perez, D.A., Barcelos, L.S., Teixeira, M.M., Santos, R.A.S., Pinho, V., Campagnole-Santos, M.J., Angiotensin-(1-7) Promotes Resolution of Eosinophilic Inflammation in an Experimental Model of Asthma. Front Immunol., 9, 2018, 58.
274. Jiang, T., Gao, L., Guo, J., Lu, J., Wang, Y., Zhang, Y., Suppressing inflammation by inhibiting the NF-kappaB pathway contributes to the neuroprotective effect of angiotensin-(1-7) in rats with permanent cerebral ischaemia. Br J Pharmacol. 167:7 (2012), 1520–1532.
275. Fujihara, S., Jaffray, E., Farrow, S.N., Rossi, A.G., Haslett, C., Hay, R.T., Inhibition of NF-kappa B by a cell permeable form of I kappa B alpha induces apoptosis in eosinophils. Biochem Biophys Res Commun. 326:3 (2005), 632–637.
276. Sousa, L.P., Carmo, A.F., Rezende, B.M., Lopes, F., Silva, D.M., Alessandri, A.L., Bonjardim, C.A., Rossi, A.G., Teixeira, M.M., Pinho, V., Cyclic AMP enhances resolution of allergic pleurisy by promoting inflammatory cell apoptosis via inhibition of PI3K/Akt and NF-kappaB. Biochem Pharmacol. 78:4 (2009), 396–405.
277. Sousa, L.P., Lopes, F., Silva, D.M., Tavares, L.P., Vieira, A.T., Rezende, B.M., Carmo, A.F., Russo, R.C., Garcia, C.C., Bonjardim, C.A., Alessandri, A.L., Rossi, A.G., Pinho, V., Teixeira, M.M., PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner. J Leukoc Biol. 87:5 (2010), 895–904.
278. Barroso, L.C., Magalhaes, G.S., Galvao, I., Reis, A.C., Souza, D.G., Sousa, L.P., Santos, R.A.S., Campagnole-Santos, M.J., Pinho, V., Teixeira, M.M., Angiotensin-(1-7) Promotes Resolution of Neutrophilic Inflammation in a Model of Antigen-Induced Arthritis in Mice. Front Immunol., 8, 2017, 1596.
279. Grinan-Ferre, C., Palomera-Avalos, V., Puigoriol-Illamola, D., Camins, A., Porquet, D., Pla, V., Aguado, F., Pallas, M., Behaviour and cognitive changes correlated with hippocampal neuroinflammaging and neuronal markers in female SAMP8, a model of accelerated senescence. Exp Gerontol. 80 (2016), 57–69.
280. Jiang, T., Xue, L.J., Yang, Y., Wang, Q.G., Xue, X., Ou, Z., Gao, Q., Shi, J.Q., Wu, L., Zhang, Y.D., AVE0991, a nonpeptide analogue of Ang-(1-7), attenuates aging-related neuroinflammation. Aging (Albany NY) 10:4 (2018), 645–657.
281. Jiang, T., Yu, J.T., Zhu, X.C., Tan, M.S., Gu, L.Z., Zhang, Y.D., Tan, L., Triggering receptor expressed on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency in senescence-accelerated mouse prone 8 mice. Neurobiol Aging 35:6 (2014), 1243–1251.
282. Jiang, T., Zhang, Y.D., Zhou, J.S., Zhu, X.C., Tian, Y.Y., Zhao, H.D., Lu, H., Gao, Q., Tan, L., Yu, J.T., Angiotensin-(1-7) is Reduced and Inversely Correlates with Tau Hyperphosphorylation in Animal Models of Alzheimer's Disease. Mol Neurobiol. 53:4 (2016), 2489–2497.
283. Perretti, M., Leroy, X., Bland, E.J., Montero-Melendez, T., Resolution Pharmacology: Opportunities for Therapeutic Innovation in Inflammation. Trends Pharmacol Sci. 36:11 (2015), 737–755.